First, we compared Siglec15 expression between the initial and recurrent glioma tissues (Figure 2A) and between the patients with relatively malignant (progressive disease [PD]) and benign (stable disease [SD], complete response [CR] or partial response [PR]) clinical courses (Figure 2A). This evidence concerns the gene SIGLEC15 and central nervous system cancer.